General mechanisms of metastasis

Cancer

Volumn 80, Issue 8 SUPPL., 1997, Pages 1529-1537

  Woodhouse, Elisa C ^a   Chuaqui, Rodrigo F ^a   Liotta, Lance A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Cancer; Chemotaxis; Growth factor; Invasion; Metastasis; Osteolysis; Osteosclerosis

Indexed keywords

COMPLEMENTARY DNA; CYTOKINE; GROWTH FACTOR; INTERLEUKIN 1; PARATHYROID HORMONE RELATED PROTEIN; PROSTAGLANDIN E; SOMATOMEDIN B; SOMATOMEDIN C; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ANGIOGENESIS; BONE METASTASIS; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL PROLIFERATION; CONFERENCE PAPER; ENZYME INHIBITION; HUMAN; OSTEOLYSIS; PRIORITY JOURNAL;

EID: 0030769477     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19971015)80:8+<1529::aid-cncr2>3.0.co;2-f     Document Type: Conference Paper

References (117)

1. Mundy GR, Yoneda T. Facilitation and suppression of bone metastasis. Clin Orthop 1995;312:34-44.
2. Hart IR, Fidler IJ. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res 1980;40:2281-7.
3. Nicolson GL. Organ specificity of tumor metastasis: role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 1988;7:143-88.
4. Srivastava A, Laidler P, Hughes LE, Woodcock J, Shedden EJ. Neovascularization in human cutaneous melanoma: a quantitative morphological and Doppler ultrasound study. Eur Cancer J Clin Oncol 1986;22:1205-9.
5. Tanigawa N, Amaya H, Matsumura M, Shimomatsuya T. Association of tumour vasculature with tumor progression and overall survival of patients with non-early gastric carcinomas. Br J Cancer 1997;75:566-71.
6. Gasparini G. Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the vicenza studies. Eur J Cancer 1996;32A:2485-93.
7. Karaiossifidi H, Kouri E, Arvaniti H, Sfikas S, Vasilaros S. Tumor angiogenesis in node-negative breast cancer: relationship with lapse free survival. Anticancer Res 1996; 16:4001-2.
8. Heimann R, Ferguson D, Powers C, Recant WM, Weichselbaum RR, Hellman S. Angiogenesis as a predictor of long-term survival for patients with node-negative breast cancer. J Natl Cancer Inst 1996;88:1764-9.
9. Silberman MA, Partin AW, Veltri RW, Epstein JI. Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 1996;79:772-9.
10. Obermair A, Kohlberger P, Bancher-Todesca D, Tempfer C, Sliutz G, Leodolter S, et al. Influence of microvessel density and vascular permeability factor/vascular endothelial growth factor expression on prognosis in vulvar cancer. Gynecol Oncol 1996;63:204-9.
11. Srivastava A, Laidler P, Davies RP, Horgan K, Hughes LE. The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. Am J Pathol 1988;133:419-23.
12. Denijn M, Ruiter DJ. The possible role of angiogenesis in the metastatic potential of human melanoma: clinicopathological aspects. Melanoma Res 1993;3:5-14.
13. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248:1408-10.
14. Maione TE, Sharpe RJ. Development of angiogenesis inhibitors for clinical applications. Trends Pharmacol Sci 1990;11:457-61.
15. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
16. Danen EHJ, van Muijen GNP, Ruiter DJ. Role of integrins as signal transducing cell adhesion molecules in human cutaneous melanoma. Cancer Surv 1995;24:43-65.
17. Hynes RO. Integrins: versality, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
18. Humphries MJ, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986;233:467-70.
19. Davies J, Warwick J, Totty N, Philip R, Helfrich M, Horton M. The osteoclast functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol 1989; 109:1817-26.
20. Horton MA, Davies J. Perspectives: adhesion receptors in bone. J Bone Miner Res 1989;4:803-8.
21. 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 1996;5:127-35.
22. 1 into tumor cells. Am J Pathol 1996;148:55-61.
23. Okada T, Hawley RG. Adhesion molecules involved in the binding of murine myeloma cells to bone marrow stromal elements. Int Cancer 1995;63:823-30.
24. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein 1 (osteopontin, 2 ar) as a consequence of neoplastic transformation. Anticancer Res 1989;9:1291-1300.
25. Denhardt DT, Guo X. Osteopontin: a protein with diverse functions. FASEB J 1993;7:1475-82.
26. Denhardt DT, Chambers AF. Overcoming obstacles to metastasis-defenses against host defenses: osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994;56:48-51.
27. Bussemakers MJ, Van Moorselaar RA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, et al. Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-22.
28. Vleminckx K, Vakaet L, Mareel M, Fiers W, Roy FV. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion supression role. Cell 1991;66:107-19.
29. Mbalaviele G, Dunstan CR, Susaki A, Williams PJ, Mundy GR, Yoneda T. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. Cancer Res 1996;56:4063-70.
30. Liotta LA. Tumor invasion and metastasis - role of the extracellular matrix. Cancer Res 1986;46:1-7.
31. Liotta LA, Kleinerman J, Saidel G. Quantitative relationships of intravascular tumor cells: tumor vessels and pulmonary metastases following tumor implantation. Cancer Res 1974;34:997-1003.
32. Nicolson GL. Gene expression, cellular diversification and tumor progression to the metastatic phenotype. Bioessays 1991;13:337-42.
33. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-86.
34. Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol 1993;10:302-13.
35. Talhouk RS, Bisell MJ, Werb Z. Coordinated expression of extracellular matrix degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol 1992;118:1271-82.
36. Wu DY, Goldberg DJ. Regulated tyrosine phosphorylation at the tips of growth cone filopodia. J Cell Biol 1993;123:653-64.
37. Lola PK, Graham CH. Mechanisms of trophoblast invasiveness and their control: the role of the proteases and protease inhibitors. Cancer Metastasis Rev 1990;9:369-80.
38. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
39. Schirrmacher V. Cancer metastasis: experimental approaches, theoretical concepts, and impacts for treatment strategies. Adv Cancer Res 1985;43:1-73.
40. Condeelis J. Life at the leading edge: the formation of cell protrusions. Annu Rev Physiol 1993;9:411-44.
41. Stossel TP. On the crawling of animal cells. Science 1993;260:1086-94.
42. Guirguis R, Margulies I, Taraboletti G, Liotta L. Cytokine-induced pseudopodial protrusion is coupled to tumor cell migration. Nature 1987;329:261-3.
43. Dong C, Aznavoorian S, Liotta LA. Two phases of pseudopod protrusion in tumor cells revealed by micropipette. Microvasc Res 1994;47:55-67.
44. Damsky CH, Werb Z. Signal transduction by integrin receptors for extracellular matrix: cooperative processing of extracellular information. Curr Opin Cell Biol 1992;4:772-81.
45. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990;6:121-5.
46. Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA, Goldberg GI. SV-40 transformed human lung fibroblasts secrete a 92-kDa type IV collagenase which is identical to that secreted by normal human macrophages. J Biol Chem 1989;264:17213-21.
47. Fessier L, Duncan K, Tryggvason K. Identification of the procollagen IV cleavage products produced by a specific tumor collagenase. J Biol Chem 1984;259:9783-9.
48. Ray JM, Stetler-Stevenson WG. The role of matrix metalloproteases and their inhibitors in tumor invasion, metastasis, and angiogenesis. Eur Respir J 1994;7:2062-72.
49. Arkona C, Wiederanders B. Expression, subcellular distribution and plasma membrane binding to cathepsin B and gelatinases in bone metastatic tissue. Biol Chem 1996;377:695-702.
50. Welgus HG, Stricklin GP. Human skin fibroblast collagenase inhibitor: comparative studies in human connective tissues, serum, and amniotic fluid. J Biol Chem 1983;258:12259-64.
51. Stetler-Stevenson WG, Krutzsch HC, Liotta LA. Tissue inhibitor of metalloproteinase (TIMP-2): a new member of the metalloproteinase inhibitor family. J Biol Chem 1989; 264:17374-8.
52. Goldberg GI, Marmer BL, Grant GA, Eisen AZ, Withelm A, He C. Human 72 kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteinases designated TIMP-2. Proc Natl Acad Sci USA 1989;86:8207-11.
53. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72 kDa and 92 kDa gelatinases by TIMP-2. J Biol Chem 1991;266:13070-5.
54. Leco KJ, Khokha R, Pavioff N, Hawkes SP, Edwards DR. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem 1994;269:9352-60.
55. De Clerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 1992;52:701-8.
56. Stetler-Stevenson WG, Krutzsch HC, Wacher MP, Margulies IMK, Liotta LA. The activation of human type IV collagenase proenzyme: sequence identification of the major conversion product following orangomercurial activation. J Biol Chem 1989;264:1353-6.
57. Melchiori A, Albini A, Ray JM, Stetler-Stevenson WG. Inhibition of tumor cell invasion by a highly conserved peptide sequence from the matrix metalloprotreinase enzyme prosegment. Cancer Res 1992;52:2353-6.
58. Fotouhi N, Lugo A, Visnick M, Lusch L, Walsky R, Coffey JW, et al. Potent peptide inhibitors of stromelysin based on the prodomain region of matrix metalloproteinases. J Biol Chem 1994;269:30227-31.
59. Schwartz MA, Van Wart HE. Eight synthetic inhibitors of bacterial and mammalian interstitial collagenases. Prog Med Chem 1992;29:271-334.
60. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (Batimastat) inhibits human colon tumor growth and spread in patient-like orthotopic model in nude mice. Cancer Res 1994;54:4726-8.
61. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53:2087-91.
62. Thorgeirsson UP, Liotta LA, Kalebic T, Margulies IM, Thomas K, Rios-Candelore M, et al. Effect of natural protease inhibitors and a chemoattractant on tumor invasion in vitro. J Natl Cancer Inst 1982;69:1049-54.
63. Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G, et al. Antisense RNA-induced reduction in murine TIMP level confers oncogenicity on Swiss 3T3. Science 1989;243:947-50.
64. Albini A, Melchiori A, Santi L, Liotta LA, Brown PD, Stetler-Stevenson WA. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991;83:775-9.
65. De Clerck Y, Szpirer C, Aly MS, Cassiman J-J, Eeckhout Y, Rousseau G. The gene for tissue inhibitor of metalloproteinase 2 is localized on human chromosome arm 17q25. Genomics 1992;14:782-4.
66. Gherardi E, Stoker M. Hepatocyte growth factor - scatter factor: mitogen, motogen, and met. Cancer Cells 1991;3:227-32.
67. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ 1990;1:325-31.
68. Stracke ML, Krutzsch HC, Unsworth EJ, Årrestad A, Cioce V, Schiffmann E, et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992;267:2524-9.
69. Naldini L, Weidner KM, Vigna E, Gaudino G, Bardelli AC, Ponzerto RC, et al. Scatter factor and hepatocyte growth factor are indistinguishable ligands for the MET receptor. EMBO J 1991;10:2867-78.
70. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
71. Santos OF, Moura LA, Rosen EM, Nigam SK. Modulation of HGF-induced tubulogenesis and branching by multiple phosphorylation mechanism. Dev Biol 1993;159:535-48.
72. Murata J, Lee HY, Clair T, Krutzsch HC, Arestad A, Sobel ME, et al. cDNA cloning of the human tumor motility-stimulating protein, autotaxin, reveals a homology with phosphodiester-ases. J Biol Chem 1994;269:30479-84.
73. Basara ML, McCarthy JB, Barnes DW, Furcht LT. Stimulation of haptotaxis and migration of tumor cells by serum spreading factor. Cancer Res 1985;45:2487-94.
74. McCarthy JB, Furcht LT. Laminin and fibronectin promote the haptotactic migration of B16 mouse melanoma cells in vitro. J Cell Biol 1984;98:1474-80.
75. Tchao R. Novel forms of epithelial cell motility on collagen and on glass surfaces. Cell Motil 1982;2:333-41.
76. Klominek J, Robert KH, Sundqvist KG. Chemotaxis and haptotaxis of human malignant mesothelioma cells: effects of fibronectin, laminin, type IV collagen, and an autocrine motility factor-like substance. Cancer Res 1993;53:4376-82.
77. Taraboletti G, Roberts DD, Liotta LA. Thrombospondin-induced tumor cell migration: haptotaxis and chemotaxis are mediated by different molecular domains. J Cell Biol 1987;105:2409-15.
78. 3 subunit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell Biol 1990;117:1101-7.
79. Mundy GR, DeMartino S, Rowe DW. Collagen and collagen-derived fragments are chemotactic for tumor cells. J Clin Invest 1981;68:1102-5.
80. Waas JA, Varani J, Piontek GE, Ward PA, Orr FW. Responses of normal and malignant cells to collagen, collagen-derived peptides and the CS-related tumor cell chemotactic peptide. Cell Differ 1981;10:329-32.
81. Mundy GR, Poser JW. Chemotactic activity of the gamma-carboxyglutamic acid containing protein in bone. Calcif Tissue Int 1983;35:164-8.
82. Orr FW, Millar-Book W, Singh G. Chemotactic activity of bone and platelet-derived TGF-beta for bone-metastasizing rat Walker 256 carcinoma cells. Invasion Metastasis 1990;10:241-52.
83. Stracke ML, Kohn EC, Aznavoorian S, Wilson LL, Salomon D, Krutzsch HC, et al. Insulin-like growth factors stimulate chemotaxis in human melanoma cells. Biochem Biophys Res Commun 1988;153:1076-83.
84. Wang JM, Taraboletti G, Matsushima K, Van Damme J, Mantovani A. Induction of haptotactic migration of melanoma cells by neutrophil activating protein/interleukin-8. Biochem Biophys Res Commun 1990;169:165-70.
85. 1 receptors. J Cell Biol 1990; 110:1211-5.
86. Edward M, MacKie RM. Cell-cell and cell-extracellular matrix interactions during melanoma cell invasion and metastasis. Melanoma Res 1993;3:227-34.
87. Halaban R, Kwon B, Ghosh S, Delli Bovis P, Baird A. bFGF as an autocrine growth factor for human melanocytes. Oncogene Res 1988;3:177-86.
88. Rodeck U, Backer D, Herlyn M. Basic fibroblast growth factor in human melanomas. Cancer Cells 1991;3:308-11.
89. Becker D, Meter CB, Herlyn M. Proliferation of human malignant melanomas is inhibited by antisense oligodeoxy-nucleotides targeted against basic fibroblast growth factor. EMBO J 1989;8:3685-91.
90. Schadendorf D, Moller A, Algermissen B, Worm M, Sticherling M, Czarnetzki BM. Interleukin 8 (IL-8) produced by human malignant melanoma cells in vitro is an essential autocrine growth factor. J Immunol 1993;151:2667-75.
91. Blat C, Bohlen P, Villaudy J, Chatelain G, Golde A, Harel L. Isolation and amino terminal sequence of a novel cellular growth inhibitor (inhibitory diffusible factor 45) secreted by 3T3 fibroblasts. J Biol Chem 1989;264:6021-4.
92. Kurtz A, Vogel F, Funa K, Heldin CH, Grosse R. Developmental regulation of mammary derived growth inhibitor expression in bovine mammary tissue. J Cell Biol 1990; 110:1779-89.
93. de Wit PEJ, Moretti S, Koenders PG, Wetterman AJ, Van Muijen GNP, Gianotti B, et al. Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992;99:168-73.
94. Hauschka PV, Mavrakos AE, Iafrati MD, Doleman SE, Klagsburn M. Growth factors in bone matrix: isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem 1986;261:12665-74.
95. Bautista CM, Mohan S, Baylink DJ. Insulin-like growth factors I and II are present in the skeletal tissue of ten vertebrates. Metabolism 1990;39:96-100.
96. Lahm H, Suardet L, Laurent PL, Fischer JR, Ceyhan A, Givel JC, et al. Growth regulation and co-stimulation of human colorectal cancer cell lines by insulin-like growth factors I, II and transforming growth factor α. Br J Cancer 1992; 65:341-6.
97. Reddy KB, Mangold GL, Tandon AK, Yoneda T, Mundy GR, Zilberstein A, et al. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res 1992;52:3636-41.
98. Koutsilieris M, Frenette G, Lazure C, Lehoux JG, Govindan MV, Poychronakos C. Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res 1993;13:481-6.
99. Globus RK, Plouet J, Gospodarowicz D. Cultured bovine bone cells synthesize basic fibroblast growth factor and store it in their extracellular matrix. Endocrinology 1989;124:1539-47.
100. Littlewood AJ, Russell J, Harvey GR, Hughes DE, Russell RG, Gowen M. The modulation of expression of IL-6 and its receptor in human osteoblasts in vitro. Endocrinology 1991;129:1513-20.
101. Cleave M, Hsieh JT, Gao C, von Eschenbach AC, Chung LWK. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991;51:5753-61.
102. Siegall CB, Schwab G, Nordan RP, FitzGerald DJ, Pastan I. Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells. Cancer Res 1990;50:7786-8.
103. Rosol TJ, Capen CC, Horst RL. Effects of infusion of human parathyroid hormone-related protein-(1-40) in nude mice: histomorphometric and biochemical investigations. J Bone Miner Res 1988;3:699-706.
104. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, et al. The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in co-cultures with mouse spleen cells. Endocinology 1989;125:1805-13.
105. Jilka RL, Hamilton JW. Evidence for two pathways for stimulation of collagenolysis in bone. Calcif Tissue Int 1985; 37:300-6.
106. Thomson BM, Mundy GR, Chambers TJ. Tumor necrosis factor alpha and beta induce osteoblastic cells to stimulate osteoclastic bone resorption. J Immunol 1987;138:775-9.
107. Powell GJ, Southby J, Danks JA, Stillwell RG, Hayman JA, Henderson MA, et al. Localization of parathyroid hormonerelated protein in breast cancer metastasis: increased incidence in bone compared with other sites. Cancer Res 1991;51:3059-61.
108. Southby J, Kissin MW, Danks JA, Hayman JA, Mosley JM, Henderson MA, et al. Immunhistochemical localization of parathyroid hormone-related protein in breast cancer. Cancer Res 1990;50:7710-6.
109. Bundred NJ, Ratcliffe WA, Walker RA, Coley S, Morrison JM, Ratcliffe JG. Parathyroid hormone related protein and hypercalcaemia in breast cancer. Br Med J 1991;303:1506-9.
110. Guise TA, Yin JJ, Taylorn SD, Kumagai Y, Dallas M, Boyce BF, et al. Evidence for a causal role of parathyroid hormonerelated protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
111. Liang P, Pardee AB. Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992;257:967-71.
112. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-7.
113. Diatchenko L, Lau YFC, Campbell AP, Chechik A, Moqadam F, Huang B, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissuespecific cDNA probes and libraries. Proc Natl Acad Sci USA 1996;93:6025-30.
114. Hubank M, Schatz DG. Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994;22:5640-8.
115. Krizman DB, Chuaqui RF, Meltzer PS, Trent JM, Duray PH, Linehan WM, et al. Construction of a representative cDNA library from prostatic intraepithelial neoplasia. Cancer Res 1996;56:5380-3.
116. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science 1996;274:998-1001.
117. Schena M, Shalon D, Davis R, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 1995;270:467-70.